TL;DR: Epinoma does not publish a price list we can verify, which is normal for Healthcare companies at this stage. Below: what we can confirm, how to get a real quote, and 8 comparable tools to benchmark the number against.
What is verifiable about Epinoma pricing, how to get a real quote, and 8 comparable tools to price it against.
Last verified:
Not in any source we can verify. Epinoma is a Y Combinator-backed Healthcare company from the Summer 2021 batch, and companies at this stage usually quote per customer rather than publish rate cards. We will not guess at a number — anything quoted elsewhere without a source is guesswork too. The company profile we work from is the Y Combinator listing; the current figure has to come from Epinoma directly.
These are the closest comparable tools, matched on what Epinoma actually does. Price each one alongside it — stage and team size are a reasonable proxy for where a vendor sits on price.
| Compare against | What it does | Stage | Team |
|---|---|---|---|
| Biocogniv | — | YC Summer 2020 | 6 |
| Docbot | — | YC Winter 2019 | — |
| Ditto Biosciences | Evolutionary intelligence for autoimmune disease | YC Winter 2026 | 3 |
| Excepgen | — | YC Winter 2019 | 3 |
| Diffuse Bio | Generative AI for protein design | YC Winter 2023 | 10 |
| Synvivia | Synvivia applies chemical control over cell behavior | YC Summer 2016 | 4 |
| Modulari-T | We teach your immune system to attack and cure cancer | YC Winter 2023 | 4 |
| TwentyTwo | AI infrastructure for biosecurity | YC Summer 2025 | 3 |
That depends on a number we cannot see, so judge it on what we can: Epinoma is currently Active with a team of around 8. A small team means faster support and more negotiating room, but more risk of the product changing direction. A larger or public vendor costs more and moves slower. If price is the deciding factor, the earlier-batch companies in the table are usually the ones still competing on it.
See all Epinoma alternatives compared →
Built by LemStudio
Loading interactive view…